SAPA-GP Webinar welcome you to attend:BioVerse: Where Science Sparks Business【Episode 004】Introduction
In the throes of a harsh capital winter, the biotech industry faces layoffs, delistings, and mergers, dominating today’s headlines. When will this financial chill end? How does it compare to previous winters? Explore the biotech survival handbook and gain insights from Les Funtleyder on navigating this challenging landscape.
Join us on EP004 to weather the storm and preserve energy forbrighter days in the global biotech industry.
CFO, Investor, Professor, Author
Leon ‘Jun’ Tang, Ph.D., M.S.
Founder of InScienceWeTrust
Partners & Collaborators:
Date and Time:
Wednesday, Dec 13, 8:30 AM to 9:30 AM (EST)
Wednesday, Dec 13, 9:30 PM to 10:30 PM (北京时间)
Les FuntleyderCFO, Investor
Mr. Funtleyder has a 20-year track record of healthcare investing and is currently a Healthcare Portfolio Manager at E Squared Capital Management where he is responsible for conducting fundamental and valuation analysis of public and private companies within the healthcare industry. While at E squared Les has had five IPO exits including serving as CFO of one of the portfolio companies.
Prior to E Squared, Mr. Funtleyder was the Director of Strategic Investments and Communications for Opko Health. In this role he participated in over $2 billion in transactions including acquisitions, strategic investments, and licensing deals. He also led all corporate and product communication efforts for the $5 billion company.
Les was a long-time portfolio manager and healthcare strategist for the Miller Tabak Health Care Transformation Fund (Symbol: MTHFX) a mutual fund dedicated to investing in transformative healthcare companies.
He joined Miller Tabak, after managing a healthcare portfolio for Provident Advisors, a hedge fund in Minneapolis, Minnesota. Before joining Provident, Les worked as a medical device analyst at UBS Warburg. He also covered Biotechnology stocks at Bigelow and Company. His industry experience includes directing clinical and business research at Innovative Health Solution, a joint venture of Merck and Wyeth, and as a consultant to HMOs and hospitals for Coopers & Lybrand and Health Strategies Group. He started his healthcare career at Empire Blue Cross/Blue Shield where he developed his approach to determining how products and services should get reimbursed, a skill that is vital in making healthcare companies successful.
Mr. Funtleyder wrote Healthcare Investing: Profiting from the New World of Pharma, Biotech, and Health Care Services (McGraw Hill), which bridges the gap between health reform, innovation and investing. He is widely quoted in the Wall Street Journal, the New York Times, and the Financial Times, and is a frequent guest on CNBC, Bloomberg and NPR for his perspective on the healthcare sector and its constituent companies. He is also a consulting partner to Bluecloud Health, a Sub-Saharan healthcare private equity fund and an advisor to Zentalya, a venture capital firm focused on South American healthcare. He currently sits on the Board of Directors for Applied Therapeutics (NASDAQ: APLT) and Reviva Pharma (NASDAQ: RVPH).
Lastly, Les is currently an Adjunct Professor of Public Health at Columbia University. Les earned his Master of Public Health from Columbia University Mailman School of Public Health, and studied English and Economics at Tulane University.